Real-world translation from diagnostic workup to anti-amyloid treatment eligibility in tertiary care settings: the biological shift captured by amyloid PET (EANM 2026) - Sep 29, 2026 - Abstract #OP-380; Pres time: Oct 19, 2026; 09:45 AM - 11:15 AM; Location: Hall F1; "Following the launch of a Donanemab compassionate use program in Italy (10/2025), patients began being referred for amyloid-PET specifically to assess treatment eligibility... Whereas the Diagnostic-Cohort spanned the full biological spectrum of amyloid deposition, the Eligibility-Cohort displayed a more dichotomous and advanced biological pattern despite earlier clinical staging. Patients referred for treatment were either unexpectedly PET-negative (despite CSF-results) or showed high CL values even at the MCI stage. These findings suggest that the more "typical" AD clinical presentation among patients currently selected for DMTs in real-world settings may be associated with more advanced biological staging despite mild clinical symptoms, highlighting a shift in patient profiles as the workflow moves from diagnosis to eligibility."
Amyloid PET • Clinical • Real-world • Real-world evidence • Alzheimer's Disease • CNS Disorders • Dementia • APOE
|
|
C. Poggio 1; F. Roveta 2; E. Rubino 2; M. Losa 3; M. Laudadio 2; C. Luppi 4; M. Zotta 1; G. Rovera 1; A. Lesca 1; S. Raffa 5; L. Sofia 5; F. Massa 6; M. Massaia 4; D. Imperiale 7; L. Roccatagliata 8; I. Rainero 2; M. Bozzali 2; M. Pardini 3; S. Morbelli 1
|